---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42648891.md"
description: "$Regencell Bioscience(RGC.US) has dropped another -14%. It was previously pushed up by a short squeeze, but now it's under pressure from a DOJ investigation, class-action lawsuits, and widening losses. For this kind of purely sentiment-driven small-cap Chinese medicine concept stock that's falling, does it count as an opportunity? I won't touch it myself — the decline of a squeeze stock usually isn't a one-off event. Once the shareholding structure loosens, any rebound won't be able to retain investors."
datetime: "2026-07-14T10:29:46.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42648891.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42648891.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42648891.md)
author: "[袋鼠](https://longbridge.com/en/profiles/27248405.md)"
generator: "portal-rs"
---

# $Regencell Bioscience(RGC.US) has dropped another …


### Related Stocks

- [RGC.US](https://longbridge.com/en/quote/RGC.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**